NeoLAB® Solid Tumor Liquid Biopsy Testing

Cell-free DNA analysis for solid tumor cancers

NeoLAB® Solid Tumor Liquid Biopsy is a next-generation sequencing assay for pan-cancer that includes 44 genes involved in solid tumor development and progression. This panel provides broad coverage of actionable markers supported by clinical guidelines and on-going clinical trials.

Biomarkers detected are implicated in a variety of tumor types including bladder, brain/CNS, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, kidney, liver, lung, melanoma, ovarian, pancreatic, prostate, stomach, and thyroid.

Clinical applications:

  • Identifying targetable alterations to guide treatment decision
  • Monitoring disease status
  • Detecting potential resistance to therapy and its cause

NeoLAB® Solid Tumor Liquid Biopsy detects >900 hotspot SNVs and indels across 44 genes

Genes Investigated in the NeoLAB® Solid Tumor Liquid Biopsy

AKT1 ERBB3 HRAS NTRK3
ALK ESR1 IDH1 PDGFRA
APC FBXW7 IDH2 PIK3CA
AR FGFR1 KIT PTEN
ARAF FGFR2 KRAS RAF1
BRAF FGFR3 MAP2K1 RET
CHEK2 FGFR4 MAP2K2 ROS1
CTNNB1 FLT3 MET SF3B1
DDR2 GNA11 MTOR SMADA4
EGFR GNAQ NRAS SMO
ERBB2 GNAS NTRK1 TP53

Analytic validation demonstrated

Limit of Detection (LoD) = 0.1% allele fraction for indels, 0.15% for SNV.

98.0%

ACCURACY

95.1%

SENSITIVITY

98.8%

SPECIFICITY

Results are returned within 7 calendar days after sample is received.